Drug Trial Radar · NCT07033234
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
142
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
Mar 2026
Study completion Mar 2026
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will be conducted in 2 parts (SAD and FE for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 and explore the food effect and fasting time on PK after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
HS-20118Drug
HS-20118
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, sever ity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with abnormalities of physical examinationTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with abnormalities of vital signsTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with clinical laboratory abnormalitiesTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
- Number of participants with abnormalities of electrocardiogram (ECG) parametersTime frame: Day 1 up to Day 36 (SAD), Day 1 up to Day 71 (MAD)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Hangzhou First People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.